Literature DB >> 27928014

Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins.

Daria Zoubchenok1,2, Maxime Veillette1,2, Jérémie Prévost1,2, Eric Sanders-Buell3,4, Kshitij Wagh5, Bette Korber5, Agnès L Chenine3,4, Andrés Finzi6,2,7.   

Abstract

The envelope glycoproteins (Envs) from human immunodeficiency virus type 1 (HIV-1) mediate viral entry. The binding of the HIV-1 gp120 glycoprotein to CD4 triggers conformational changes in gp120 that allow high-affinity binding to its coreceptors. In contrast to all other Envs from the same phylogenetic group, M, which possess a serine (S) at position 375, those from CRF01_AE strains possess a histidine (H) at this location. This residue is part of the Phe43 cavity, where residue 43 of CD4 (a phenylalanine) engages with gp120. Here we evaluated the functional consequences of replacing this residue in two CRF01_AE Envs (CM244 and 92TH023) by a serine. We observed that reversion of amino acid 375 to a serine (H375S) resulted in a loss of functionality of both CRF01_AE Envs as measured by a dramatic loss in infectivity and ability to mediate cell-to-cell fusion. While no effects on processing or trimer stability of these variants were observed, decreased functionality could be linked to a major defect in CD4 binding induced by the replacement of H375 by a serine. Importantly, mutations of residues 61 (layer 1), 105 and 108 (layer 2), and 474 to 476 (layer 3) of the CRF01_AE gp120 inner domain layers to the consensus residues present in group M restored CD4 binding and wild-type levels of infectivity and cell-to-cell fusion. These results suggest a functional coevolution between the Phe43 cavity and the gp120 inner domain layers. Altogether, our observations describe the functional importance of amino acid 375H in CRF01_AE envelopes. IMPORTANCE: A highly conserved serine located at position 375 in group M is replaced by a histidine in CRF01_AE Envs. Here we show that H375 is required for efficient CRF01_AE Env binding to CD4. Moreover, this work suggests that specific residues of the gp120 inner domain layers have coevolved with H375 in order to maintain its ability to mediate viral entry.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD4; CRF01_AE; Env; HIV-1; Phe43 cavity; gp120; inner domain layers

Mesh:

Substances:

Year:  2017        PMID: 27928014      PMCID: PMC5286895          DOI: 10.1128/JVI.02151-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  58 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

3.  Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding.

Authors:  Andrés Finzi; Beatriz Pacheco; Shi-Hua Xiang; Marie Pancera; Alon Herschhorn; Liping Wang; Xing Zeng; Anik Desormeaux; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

4.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

Authors:  S Gnanakaran; Marcus G Daniels; Tanmoy Bhattacharya; Alan S Lapedes; Anurag Sethi; Ming Li; Haili Tang; Kelli Greene; Hongmei Gao; Barton F Haynes; Myron S Cohen; George M Shaw; Michael S Seaman; Amit Kumar; Feng Gao; David C Montefiori; Bette Korber
Journal:  PLoS Comput Biol       Date:  2010-10-07       Impact factor: 4.475

8.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.

Authors:  C Y Kang; K Hariharan; P L Nara; J Sodroski; J P Moore
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.

Authors:  Hui Li; Shuyi Wang; Rui Kong; Wenge Ding; Fang-Hua Lee; Zahra Parker; Eunlim Kim; Gerald H Learn; Paul Hahn; Ben Policicchio; Egidio Brocca-Cofano; Claire Deleage; Xingpei Hao; Gwo-Yu Chuang; Jason Gorman; Matthew Gardner; Mark G Lewis; Theodora Hatziioannou; Sampa Santra; Cristian Apetrei; Ivona Pandrea; S Munir Alam; Hua-Xin Liao; Xiaoying Shen; Georgia D Tomaras; Michael Farzan; Elena Chertova; Brandon F Keele; Jacob D Estes; Jeffrey D Lifson; Robert W Doms; David C Montefiori; Barton F Haynes; Joseph G Sodroski; Peter D Kwong; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 12.779

Review 10.  Recombination in HIV: an important viral evolutionary strategy.

Authors:  D S Burke
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

View more
  11 in total

1.  A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity.

Authors:  Shilei Ding; Melissa C Grenier; William D Tolbert; Dani Vézina; Rebekah Sherburn; Jonathan Richard; Jérémie Prévost; Jean-Philippe Chapleau; Gabrielle Gendron-Lepage; Halima Medjahed; Cameron Abrams; Joseph Sodroski; Marzena Pazgier; Amos B Smith; Andrés Finzi
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

2.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.

Authors:  Jérémie Prévost; Daria Zoubchenok; Jonathan Richard; Maxime Veillette; Beatriz Pacheco; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Kiat Ruxrungtham; Torsak Bunupuradah; Sodsai Tovanabutra; Kwan-Ki Hwang; M Anthony Moody; Barton F Haynes; Mattia Bonsignori; Joseph Sodroski; Daniel E Kaufmann; George M Shaw; Agnès L Chenine; Andrés Finzi
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

3.  Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.

Authors:  Saumya Anang; Jonathan Richard; Catherine Bourassa; Guillaume Goyette; Ta-Jung Chiu; Hung-Ching Chen; Amos B Smith; Navid Madani; Andrés Finzi; Joseph Sodroski
Journal:  J Virol       Date:  2022-08-18       Impact factor: 6.549

4.  Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors.

Authors:  Annemarie Laumaea; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

5.  HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.

Authors:  Anjali Joshi; Emily K Cox; Melina J Sedano; Erin B Punke; Raphael Tc Lee; Sebastian Maurer-Stroh; Palvinder Kaur; Oon Tek Ng; Himanshu Garg
Journal:  Virology       Date:  2017-10-09       Impact factor: 3.616

6.  Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection.

Authors:  Franck P Dupuy; Nicole F Bernard; Lauren Nagel; Sanket Kant; Christopher Leeks; Jean-Pierre Routy; Cécile Tremblay; Réjean Thomas; Jason Szabo; Pierre Côté; Benoit Trottier; Roger LeBlanc; Danielle Rouleau
Journal:  J Virol       Date:  2021-09-29       Impact factor: 5.103

7.  The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site.

Authors:  Jérémie Prévost; William D Tolbert; Halima Medjahed; Rebekah T Sherburn; Navid Madani; Daria Zoubchenok; Gabrielle Gendron-Lepage; Althea E Gaffney; Melissa C Grenier; Sharon Kirk; Natasha Vergara; Changze Han; Brendan T Mann; Agnès L Chénine; Adel Ahmed; Irwin Chaiken; Frank Kirchhoff; Beatrice H Hahn; Hillel Haim; Cameron F Abrams; Amos B Smith; Joseph Sodroski; Marzena Pazgier; Andrés Finzi
Journal:  mBio       Date:  2020-05-26       Impact factor: 7.867

8.  Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.

Authors:  David Easterhoff; Justin Pollara; Kan Luo; William D Tolbert; Brianna Young; Dieter Mielke; Shalini Jha; Robert J O'Connell; Sandhya Vasan; Jerome Kim; Nelson L Michael; Jean-Louis Excler; Merlin L Robb; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Sorachai Nitayaphan; Faruk Sinangil; James Tartaglia; Sanjay Phogat; Thomas B Kepler; S Munir Alam; Kevin Wiehe; Kevin O Saunders; David C Montefiori; Georgia D Tomaras; M Anthony Moody; Marzena Pazgier; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2020-01-31       Impact factor: 6.549

Review 9.  Unlocking HIV-1 Env: implications for antibody attack.

Authors:  Jonathan Richard; Shilei Ding; Andrés Finzi
Journal:  AIDS Res Ther       Date:  2017-09-12       Impact factor: 2.250

10.  High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses.

Authors:  Debashis Dutta; Samuel Johnson; Alisha Dalal; Martin J Deymier; Eric Hunter; Siddappa N Byrareddy
Journal:  PLoS One       Date:  2018-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.